📰 Abivax News
Page 2 - Abivax News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Abivax. Real-time updates on events, politics, business and more.
May 15, 2023
PARIS, FRANCE / ACCESSWIRE / May 15, 2023 / Abivax (Euronext Paris: FR0012333284 - ABVX), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system
May 4, 2023
PARIS, FRANCE / ACCESSWIRE / May 4, 2023 / Abivax (Euronext Paris: FR0012333284 - ABVX) (the "Company"), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate
May 2, 2023
The authors of the expert article published in the Journal of Crohn's and Colitis include major European and North American Key Opinion Leaders in the field of Inflammatory Bowel DiseasesThe KOLs state
April 19, 2023
Obefazimod global pivotal phase 3 program (ABTECT program) in moderate to severe ulcerative colitis (UC) early enrollment progressing according to planAbivax reports promising Phase 2b maintenance results
April 19, 2023
19.04.2023 - EQS-News: ABIVAX / Key word(s): Annual Results Abivax reports 2022 financial results and operations update 19.04.2023 / 21:00 CET/CEST The issuer is solely responsible for the content of this announcement. Abivax reports 2022 financial results and ...
April 18, 2023
Michael Ferguson has a strong track record in the biopharmaceutical industry, having held senior positions for commercialization and marketing of drugs in the field of Gastroenterology and specifically
April 18, 2023
18.04.2023 - EQS-News: ABIVAX / Key word(s): Personnel Abivax appoints Michael Ferguson as Chief Commerical Officer 18.04.2023 / 18:00 CET/CEST The issuer is solely responsible for the content of this announcement. Abivax appoints Michael Ferguson as Chief ... Seite 1
April 17, 2023
The analysis demonstrates clinical remission in 52.5% (n=114) of 217 moderate to severe ulcerative colitis (UC) patients (intent-to-treat population, ITT) after two years (96 weeks) of once-daily oral
April 5, 2023
Marc's appointment bolsters Abivax's position as a leader in the field of chronic inflammatory bowel diseasesCorinna zur Bonsen-Thomas steps down as acting Chair and remains a Board MemberProf. Hartmut
March 16, 2023
PARIS, FRANCE / ACCESSWIRE / March 16, 2023 / Abivax SA (Euronext Paris:FR0012333284 - ABVX), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune